The efforts appear to be early steps in the venture's goal of overhauling health-care benefits to make them more transparent.

The actions have raised questions about why it took public pressure before the companies altered their programs.

Rather than manufacture its own drugs, Civica Rx will act as a go-between for hospitals and drugmakers to pool demand and increase supply.

The Trump administration and Congress are gearing up for a renewed campaign to bring the companies to heel. Will it work?

The drugmaker will start airing television ads touting the website lillypricinginfo.com, along with a toll-free telephone number.

Drugmakers have said that disclosing list prices without additional context would be confusing to patients.

Many widely used copycat medications are seeing their prices fall at such a rapid rate that their makers are struggling to keep their heads above water.

Generic drugs account for more than 90 percent of U.S. prescriptions. Overcapacity and the emergence of big purchasing groups have slammed manufacturers' margins.